Search research articles
Contact Us
Filters
Showing results (1-10 of 28) with videos related to
Page
of 3
Sort By:
Journal of the National Cancer Institute
|
January 1, 1981
A case study of statistics in the regulatory process: the FD&C Red No. 40 experiments
S Lagakos, F Mosteller
Statistics in Medicine
|
November 15, 1996
HIV treatment strategies utilizing virologic and immunologic markers as criteria for changing treatments
M Elashoff, S Lagakos
Environmental Health Perspectives
|
July 1, 1990
On the consequences of model misspecification in logistic regression
M D Begg, S Lagakos
Cancer
|
April 15, 1982
Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP-16 in small-cell carcinoma of the lung
D S Ettinger, S Lagakos
The New England Journal of Medicine
|
March 10, 2001
Designing and funding clinical trials of novel therapies
K Antman, S Lagakos, J Drazen
Lancet (London, England)
|
May 15, 1993
The Concorde trial
S Lagakos, C Pettinelli, D Stein
Clinical and Diagnostic Laboratory Immunology
|
April 28, 2001
Effectiveness of remune
D Glidden, S Kim, S Lagakos
Current Opinion in Clinical Nutrition and Metabolic Care
|
May 19, 2011
The role of G-protein-coupled receptors in mediating the effect of fatty acids on inflammation and insulin sensitivity
Da Young Oh, William S Lagakos
Infectious Agents and Disease
|
October 1, 1993
Uses of CD4-lymphocyte count in AIDS treatment decisions
V De Gruttola, R Gelman, S Lagakos
Journal of Lipid Research
|
April 19, 2008
Metabolism of apical versus basolateral sn-2-monoacylglycerol and fatty acids in rodent small intestine
Judith Storch, Yin Xiu Zhou, William S Lagakos
Page
of 3
Search research articles
Search
Showing results (1-10 of 28) with videos related to
Sort By:
Page
of 3
Journal of the National Cancer Institute
|
January 1, 1981
A case study of statistics in the regulatory process: the FD&C Red No. 40 experiments
S Lagakos, F Mosteller
Statistics in Medicine
|
November 15, 1996
HIV treatment strategies utilizing virologic and immunologic markers as criteria for changing treatments
M Elashoff, S Lagakos
Environmental Health Perspectives
|
July 1, 1990
On the consequences of model misspecification in logistic regression
M D Begg, S Lagakos
Cancer
|
April 15, 1982
Phase III study of CCNU, cyclophosphamide, adriamycin, vincristine, and VP-16 in small-cell carcinoma of the lung
D S Ettinger, S Lagakos
The New England Journal of Medicine
|
March 10, 2001
Designing and funding clinical trials of novel therapies
K Antman, S Lagakos, J Drazen
Lancet (London, England)
|
May 15, 1993
The Concorde trial
S Lagakos, C Pettinelli, D Stein
Clinical and Diagnostic Laboratory Immunology
|
April 28, 2001
Effectiveness of remune
D Glidden, S Kim, S Lagakos
Current Opinion in Clinical Nutrition and Metabolic Care
|
May 19, 2011
The role of G-protein-coupled receptors in mediating the effect of fatty acids on inflammation and insulin sensitivity
Da Young Oh, William S Lagakos
Infectious Agents and Disease
|
October 1, 1993
Uses of CD4-lymphocyte count in AIDS treatment decisions
V De Gruttola, R Gelman, S Lagakos
Journal of Lipid Research
|
April 19, 2008
Metabolism of apical versus basolateral sn-2-monoacylglycerol and fatty acids in rodent small intestine
Judith Storch, Yin Xiu Zhou, William S Lagakos
Page
of 3